Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global non-steroidal anti-inflammatory drugs market size was valued at USD 19,551.34 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.36% from 2022 to 2030. The growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market is owing to factors such as the rising prevalence of chronic pain across the globe coupled with the increase in the geriatric population globally. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in headaches, migraine, toothaches, and menstrual pain are also expected to boost the growth during the forecast period. Furthermore, the availability of a robust product portfolio of NSAIDs and rising product approvals and launch are likely to propel the growth forward during the forecast period.

The rising incidence of chronic pain is expected to boost the market growth of NSAIDs during the forecast period. For instance, according to the CDC in 2019, around 20.4% of the adult population suffered from chronic pain in the United States. The incidence of chronic pain raised with age and was highest among adults aged 65 and over. The prevalence of chronic pain in non-Hispanic whites is highest compared to Hispanic, non-Hispanic Asia, and non-Hispanic black adults. The prevalence of chronic pain in non-Hispanic white adults is around 23.6%. Thus, the higher prevalence of chronic pain is expected to spur growth as the COX-2 selective and non-selective NSAIDs are commonly used in the management of chronic pain. 

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support market growth over the forecast period. For instance, according to the CDC, it is estimated that about 1 in 4 adults in the U.S., which is around 58.5 million people, have been diagnosed with arthritis. And this arthritis is more common in women (23.5%) as compared to men (18.1%). Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

The geriatric population is more susceptible to diseases such as CVDs, cancer, diabetes, chronic pain, arthritis, and others. Thus, the rising geriatric population across the globe is expected to support market growth. For instance, according to an Administration on Ageing (AoA) report, in the United States, the population aged 65 years and older was around 54.1 million in 2019, representing over 16% of the U.S. population. Among them, around 30 million were women, and around 24.1 million were men. This population is expected to be 21.6% of the U.S. by the year 2040. Thus, the continuous surge in the geriatric population is expected to fuel the growth over the forecast period.

As a high number of market players are involved in NSAID research, production, and marketing activities, they are often engaged in formulating organic and inorganic growth strategies to widen their footprints. For instance, in August 2021, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA. Moreover, in September 2020, Dr. Reddy launched the diclofenac sodium topical gel 1% as an OTC drug for arthritis pain in the United States. Thus, owing to the various strategies adopted by market players, they are likely to boost the market growth.

The presence of a robust product portfolio of NSAID preparations is also expected to cater to the growth during the forecast period. For instance, Ketorolac tromethamine, manufactured by Pfizer Inc., is used to treat moderately severe acute pain that requires analgesia at the opioid level. Moreover, Excedrin, manufactured by the GSK Group of Companies, is a combination of paracetamol, aspirin, and caffeine and is a leading brand for treating headaches. High market penetration of key brands and the increasing introduction of combination drugs are anticipated to fuel the growth over the forecast period.

Disease Indication Insights

The arthritis segment held the largest market share of 38.02% in 2021 and is expected to maintain its dominance over the forecast period. The growth of the segment is owing to factors such as the high prevalence of arthritis and osteoarthritis, the rising geriatric population across the globe, the high prescription of NSAIDs, and a surge in the adoption of topical preparations for subsiding arthritis. According to the Arthritis Society Canada, in 2019, Canada had over 6 million arthritis cases and is expected to be around 9 million by 2040. Moreover, the availability of many approved formulations for the management of arthritis pain is also expected to spur the arthritis segment growth. For instance, Celebrix (Celecoxib Capsule), manufactured by Viatris Inc., is indicated for pain management in rheumatoid arthritis and osteoarthritis.

The migraine segment is expected to witness lucrative growth opportunities during the forecast period owing to the high prevalence of migraines and approved formulations for them. For instance, Advil migraine (Ibuprofen Capsule) manufactured by GSK plc is the only U.S. FDA-approved regime for migraine episodes. Moreover, increasing the adoption of over-the-counter non-steroidal anti-inflammatory drugs is further propelling the segment growth over the forecast period.

Route of Administration Insights

The oral segment held the largest market share in 2021 and is expected to maintain its dominance over the forecast period owing to the availability of a large pool of oral NSAIDs for pain, headache, fever, and migraine and increased sales of OTC NSAIDs. For instance, Johnson & Johnson Consumer Inc. offers its NSAID preparation Motrin (ibuprofen), which is available in dosage forms such as a tablet, capsule, liquid gel, and suspension to treat headaches and migraines. Thus, owing to the higher availability of oral NSAIDs products, the segment is expected to experience robust growth opportunities during the forecast period.

The topical segment is expected to experience the fastest growth rate over the forecast period. The wide availability of topical NSAID preparations and high demand for topical drugs are expected to fuel the growth over the forecast period. For instance, Flector (diclofenac epolamine-Topical system) manufactured by IBSA Pharma Inc., is indicated for pains due to sprains and strains.

Distribution Channel Insights

The retail pharmacy segment held the largest market share of 46.39% in 2021. The high market share of retail pharmacies can be attributed to factors such as the increasing number of NSAIDs prescriptions for pain management and the rising availability of NSAIDs as over-the-counter drugs across the globe. For instance, In August 2021, Dr. Reddy’s Laboratories Ltd re-launched OTC Naproxen Sodium Tablets USP, the store-brand equivalent of Aleve in the United States.

Furthermore, hospital pharmacies held the second largest market share owing to the high adoption rate of non-steroidal anti-inflammatory drugs for pain management in hospitalized patients. However, the online pharmacy segment is expected to grow at the fastest rate during the forecast period, owing to factors, such as increasing adoption of e-commerce and extra discounts on online medicines.

Regional Insights

North America dominated the overall market in terms of revenue in 2021, followed by Europe. Factors such as the presence of a large number of manufacturers and strategic initiatives undertaken by market players are some of the major factors driving the market's growth. Moreover, the increasing prevalence of chronic pain and arthritis is also anticipated to propel the growth forward during the forecast period.

For instance, according to the CDC, it is estimated that the prevalence of arthritis is expected to increase in the upcoming decades. By 2040, it is estimated that over 78.4 million adults will have doctor-diagnosed arthritis. Moreover, the major market players operating in the NSAIDs market have a decent presence across the region, and that is likely to propel market growth forward during the forecast period. For instance, Pfizer Inc., Johnson & Johnson Consumer Inc., and GSK Group of Companies have a decent presence across the United States and Canada.  

Asia-Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region is attributed to factors such as the increasing geriatric population, the rising prevalence of chronic pain, migraine, and headaches, along with rising product approvals and launches in the region. For instance, in May 2021, Ono Pharmaceutical Co., Ltd. launched JOYCLU 30mg intra-articular injection, for which Seikagaku received manufacturing and marketing approval in Japan in March 2021.

Key Companies & Market Share Insights

The key players that dominated the global non-steroidal anti-inflammatory drugs market in 2021 included GSK plc and Pfizer Inc. The presence of a strong product portfolio is expected to maintain a strong market share for the companies. The market is highly competitive due to numerous generic players involved in the manufacturing and marketing of NSAIDs worldwide. Moreover, various organic and inorganic developments made by market players are expected to fuel the market's growth during the forecast period. Some prominent players in the non-steroidal anti-inflammatory drugs market include:

• Pfizer Inc.

• Bayer AG

• GSK plc

• Dr. Reddy’s Laboratories Ltd

• Viatris Inc

• Teva Pharmaceutical Industries Ltd.

• Johnson And Johnson Services, Inc.

• Merck & Co., Inc.

Non-steroidal Anti-inflammatory Drugs Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For this study, Grand View Research has segmented the non-steroidal anti-inflammatory drugs market based on disease indication, route of administration, distribution channel, and region:

• Disease Indication Outlook (Revenue, USD Million; 2018 - 2030)

  • Arthritis

  • Migraine

  • Ophthalmic Diseases

  • Others

• Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

  • Oral

  • Topical

  • Others

• Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • UAE